Aller au contenu principal
Accès ouvert déclaré 2026 article

The Application Value of Chromosome Microarray Analysis in Prenatal Diagnosis of Clinically Relevant Copy Number Variations in Fetuses

0Citations signalées, ce qui n’est pas une note de qualité
1Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Objective: Exploring the clinical application value of chromosome microarray analysis (CMA) technology in detecting clinically relevant copy number variations (CNVs) in fetuses and evaluating its efficacy in prenatal diagnosis. Methods: A retrospective analysis was conducted on 2860 pregnant women undergoing prenatal diagnosis between January 2019 and August 2023. All cases received concurrent G-banded karyotyping and CMA. Detection rates were compared and stratified by clinical indications (eg, structural anomalies, increased nuchal translucency NT). CNVs were classified per ACMG guidelines. Parental origin verification and neonatal follow-up (6 months to 2 years) were performed to correlate CNVs with postnatal phenotypes. Results: CMA yielded a significantly higher overall detection rate than karyotyping (14.41% vs 10.10%, P<0.05), identifying 238 pathogenic (8.32%), 62 likely pathogenic (2.17%), and 112 VUS (3.92%) cases. The highest CMA yield occurred in fetuses with structural anomalies (26.85%), particularly multi-system defects (25.16% P/LP yield). Pathogenic yields also rose progressively with NT thickness. Of the 300 P/LP CNVs, 54.00% were microdeletions and 61.33% were <5 Mb, with DiGeorge syndrome being most prevalent (5.67%). De novo P/LP CNVs showed a significantly higher rate of abnormal postnatal phenotypes (40.00%) compared to inherited cases (10.53%, P<0.05). For VUS, inherited cases had a significantly higher postnatal normality rate (93.75%) than de novo variants (66.67%, P<0.05). Conclusion: Based on large sample data, this study confirms that CMA technology can not only improve the overall detection rate of fetal chromosomal abnormalities, but also effectively identify submicroscopic CNVs within the blind spots of traditional karyotype analysis. It serves as a high-value first-line tool for fetuses with multisystem anomalies or increased NT. Parental origin verification is critical for refining VUS interpretation and guiding pregnancy management.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
The Application Value of Chromosome Microarray Analysis in Prenatal Diagnosis of Clinically Relevant Copy Number Variations in Fetuses
Date Crossref
01/08/2026
Éditeur
Informa UK Limited
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

  • Henan Provincial People's Hospital Department of Ultrasound pays non établi dans la notice
    Établissement de santé
  • Institute of Genetics pays non établi dans la notice
    Structure de recherche

Department of Ultrasound — Henan Provincial People's Hospital et Institute of Genetics.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Prenatal Screening and DiagnosticsGenomic variations and chromosomal abnormalitiesFetal and Pediatric Neurological Disorders

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.